Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wutte, A; Plank, J; Bodenlenz, M; Magnes, C; Regittnig, W; Sinner, F; Ronn, B; Zdravkovic, M; Pieber, TR.
Proportional dose-response relationship and lower within-patient variability of insulin deternir and NPH insulin in subjects with type 1 diabetes mellitus
EXP CLIN ENDOCRINOL DIABETES. 2007; 115(7): 461-467.
Doi: 10.1055/s-2007-976512
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Wutte Andrea-Maria
- Co-Autor*innen der Med Uni Graz
- Pieber Thomas
- Regittnig Werner
- Sinner Frank Michael
- Weiss Manfred
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This study was conducted to evaluate the dose ratio of insulin detemir and neutral protamine Hagedorn (NPH) insulin over a range of therapeutically relevant subcutaneous doses. The study was a randomized, double-blind, crossover 24-h-iso-glycemic clamp trial in 12 C-peptide-negative type 1 diabetic patients. Each subject received, by an incomplete block design selection, two of three possible doses of insulin detemir (0.15, 0.3, 0.6 U/kg) and NPH insulin (0.15, 0.3, 0.6 IU/kg), respectively. A detailed assessment of endogenous glucose production (EGP) and glucose uptake was performed, by use of stable isotopic labeled glucose tracer (D-[6,6- (2)H (2)] glucose). Dose proportionality was observed within the tested dose range. Regarding unit dose ratio, 0.68 U insulin detemir equals 1 IU NPH insulin (95% CI [0.35; 1.30]). There was no statistically significant difference in effect on the area under the curve (AUC) of glucose infusion rate (GIR) (AUC (GIR)) and the maximal GIR (GIR (max)) values, when comparing U (insulin detemir) to IU (NPH insulin). The pharmacodynamic within-subject profile was lower with insulin detemir in regard to AUC (GIR 0-24 h), GIR (max) and duration of action ( P<0.05). There was a tendency for a greater reduction of EGP with insulin detemir than with NPH insulin in regard to the area over the curve (AOC) of EGP in 24 hours (AOC (EGP 0-24 h)) ( P=0.07) and minimal EPG (EGP (min)) ( P=0.02). These data show that insulin detemir is dose-proportional to NPH insulin in type 1 diabetic patients at clinically relevant doses. The data indicate that insulin detemir has a lower degree of within-subject variability.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Area Under Curve -
- Blood Glucose - analysis
- Blood Glucose - metabolism
- Cross-Over Studies -
- Diabetes Mellitus, Type 1 - drug therapy
- Dose-Response Relationship, Drug -
- Double-Blind Method -
- Female -
- Glucose - administration & dosage
- Humans -
- Injections, Subcutaneous -
- Insulin - administration & dosage
- Insulin - analogs & derivatives
- Insulin - pharmacokinetics
- Insulin - therapeutic use
- Insulin Detemir -
- Insulin, Isophane - administration & dosage
- Insulin, Isophane - pharmacokinetics
- Insulin, Isophane - therapeutic use
- Insulin, Long-Acting -
- Male -
- Middle Aged -
- Find related publications in this database (Keywords)
- glucose uptake
- glucose production
- glucose clamp
- tracer infusion technique